Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Forum of Clinical Oncology
Volume 12 (2021): Issue 1 (May 2021)
Open Access
Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
Engy M Aboelnaga
Engy M Aboelnaga
and
Wafaa El-beshbishi
Wafaa El-beshbishi
| Aug 09, 2021
Forum of Clinical Oncology
Volume 12 (2021): Issue 1 (May 2021)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Research Article
Published Online:
Aug 09, 2021
Page range:
12 - 21
Received:
Jul 05, 2019
Accepted:
Nov 05, 2019
DOI:
https://doi.org/10.2478/fco-2019-0015
Keywords
Capecitabine
,
Metastatic breast cancer
,
Low dose
,
Standard dose
,
Efficacy
,
Safety
© 2021 Engy M Aboelnaga et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Engy M Aboelnaga
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University
Egypt
Wafaa El-beshbishi
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University
Egypt